COMy 2023 | Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of the peptide–drug conjugate melflufen for treating patients with relapsed/refractory multiple myeloma (R/R MM). Dr Richardson explains the cytotoxic mechanism of melflufen and notes its advantages over traditional cytotoxic therapies from the patient perspective. Dr Richardson further highlights the Phase III LIGHTHOUSE study (NCT04649060), which evaluated the safety and efficacy of melflufen, daratumumab, and dexamethasone combination therapy in patients with R/R MM. This study demonstrated promising results, including positive safety signals and advantages in progression-free survival (PFS) and overall survival (OS). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda
Oncopeptides, Celgene/BMS, Karyopharm, Takeda
